Tuesday, September 16, 2014 3:38:55 PM
1) The method of use patent going to 2025 - the generic company could be sued by Cortex if they were to advertise the use of their generic Dronabinol for Sleep Apnea.
2) Proprietary formulations, and 2 pending dosing patents -
-- a) Proprietary dose - presumably the lowest 2.5 mg dose, but not sure how this would provide patent protection from a generic 2.5 mg product (?)
-- b) Pulse dose formulation - to provide efficacy over the entire night. This is interesting but apparently not yet developed - a 2.5 mg pill which would also contain an additional delayed release 2.5 mg amount of Dronabinol which will kick in at night after the initial 2.5 wears off. Dronabinol's halflife is 2-4 hours, so it only covers the first half night's sleep. But in the Phase 2a it was noted that the low 2.5 mg dose provided the same efficacy as the high 10 mg dose for the first ~ four hours of sleep, creating the opportunity for Cortex to produce a patented dosage form which will include an extra 2.5 mg 'booster' for hours 4-8 hours of sleep. So a clever way to make the Cortex product stand out in the marketplace against generics, although actually developing this dosing form and running some trials will take time.
3) 3rd Party payers - the fact that off-label use of generics and medical marijuana are not covered by 3rd party payers. I wonder though, if once the FDA approval for Sleep Apnea occurs, it then won't be considered off label anymore (?) Hopefully Dr. Lippa will elaborate more on this strategy in future presentations.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM